EPH66 Descriptive Analysis of Adverse Events Reported Associated with the Use of Tigecycline or Minocycline Using the FDA Adverse Event Reporting System Database from 2008 to 2021

To overcome bacterial resistance, more potent antibiotics with broader spectrum of activity were discovered like tigecycline, which is a minocycline derivative. However, the current literature suggests need for an investigation regarding occurrence adverse events and tigecycline. This study aimed to explore frequency associated use tigecycline from FDA reporting system (FAERS) database. retrospective based on FAERS database that descriptively analyzes all reports or 2008 2021. includes congenital anomaly, death, disability, life-threatening condition, Required Intervention. We found 251,724 reported between first quarter second 2021 234,369 patients. The main drug-related issues, musculoskeletal, dermatological, blood coagulation, pain discomfort, nausea and/or vomiting, respiratory AEs. had total 150235 outcomes Of these outcomes, hospitalization accounted highest percentage (27.99%), followed by death (9.77% 6.46 % respectively). Drug-related musculoskeletal AEs most ADEs use. Hospitalization outcome drugs. More pharmacoepidemiology research warranted validate drug-event association.